NO20084732L - Substituerte 5-fenylamino- 1, 3, 4-oksadiazol-2-ylcarbonylamino-4-fenoksy-cycloheksane karboksylsyre som inhibitorer av acetyl koenzym A diacylglyserol acyltransferase - Google Patents
Substituerte 5-fenylamino- 1, 3, 4-oksadiazol-2-ylcarbonylamino-4-fenoksy-cycloheksane karboksylsyre som inhibitorer av acetyl koenzym A diacylglyserol acyltransferaseInfo
- Publication number
- NO20084732L NO20084732L NO20084732A NO20084732A NO20084732L NO 20084732 L NO20084732 L NO 20084732L NO 20084732 A NO20084732 A NO 20084732A NO 20084732 A NO20084732 A NO 20084732A NO 20084732 L NO20084732 L NO 20084732L
- Authority
- NO
- Norway
- Prior art keywords
- ylcarbonylamino
- oxadiazol
- phenylamino
- phenoxy
- inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
- C07D271/113—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Molecular Biology (AREA)
- Neurology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Child & Adolescent Psychology (AREA)
- AIDS & HIV (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US80929806P | 2006-05-30 | 2006-05-30 | |
PCT/GB2007/001990 WO2007138311A1 (en) | 2006-05-30 | 2007-05-29 | Substituted 5- phenylamino- 1, 3, 4-oxadiaz0l-2-ylcarbonylamino-4-phenoxy-cyclohexane carboxylic acid as inhibitors of acetyl coenzyme a diacylglycerol acyltransferase |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20084732L true NO20084732L (no) | 2008-12-12 |
Family
ID=38255814
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20084732A NO20084732L (no) | 2006-05-30 | 2008-11-10 | Substituerte 5-fenylamino- 1, 3, 4-oksadiazol-2-ylcarbonylamino-4-fenoksy-cycloheksane karboksylsyre som inhibitorer av acetyl koenzym A diacylglyserol acyltransferase |
Country Status (18)
Country | Link |
---|---|
US (1) | US8084478B2 (de) |
EP (1) | EP2041100B1 (de) |
JP (1) | JP2009538892A (de) |
KR (1) | KR20090012349A (de) |
CN (1) | CN101472905B (de) |
AT (1) | ATE492541T1 (de) |
AU (1) | AU2007266796B2 (de) |
BR (1) | BRPI0712802A2 (de) |
CA (1) | CA2651710A1 (de) |
DE (1) | DE602007011446D1 (de) |
ES (1) | ES2356097T3 (de) |
HK (1) | HK1128687A1 (de) |
IL (1) | IL195126A0 (de) |
MX (1) | MX2008015228A (de) |
NO (1) | NO20084732L (de) |
NZ (1) | NZ572586A (de) |
WO (1) | WO2007138311A1 (de) |
ZA (1) | ZA200809690B (de) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2005315430B2 (en) | 2004-12-14 | 2010-05-27 | Astrazeneca Ab | Oxadiazole derivatives as DGAT inhibitors |
AR058562A1 (es) * | 2005-12-22 | 2008-02-13 | Astrazeneca Ab | Derivados de pirimido [4,5 b] (1,4) oxazinas , procedimientos de obtencion y su uso como inhibidores de acetil coa y dgat 1 |
ES2375576T3 (es) | 2006-03-31 | 2012-03-02 | Novartis Ag | Derivados del �?cido (4-(4-[6-(trifluorometil-piridin-3-ilamino)-heteroarilo con contenido de n]-fenil)-ciclohexil)-acético y sus usos farmacéuticos. |
EP2041099A1 (de) * | 2006-05-30 | 2009-04-01 | AstraZeneca AB | 1,3,4-oxadiazolderivate als dgat1-inhibitoren |
ATE500251T1 (de) * | 2006-06-08 | 2011-03-15 | Astrazeneca Ab | Benzimidazole und ihre verwendung zur behandlung von diabetes |
CA2695434A1 (en) * | 2007-08-17 | 2009-02-26 | Astrazeneca Ab | Chemical compounds 979 |
AR066169A1 (es) | 2007-09-28 | 2009-07-29 | Novartis Ag | Derivados de benzo-imidazoles, utiles para trastornos asociados con la actividad de dgat |
WO2009081195A1 (en) | 2007-12-20 | 2009-07-02 | Astrazeneca Ab | Carbamoyl compounds as dgat1 inhibitors 190 |
TW201010700A (en) | 2008-08-25 | 2010-03-16 | Piramal Lifesciences Ltd | Diacylglycerol acyltransferase inhibitors |
CN102395572A (zh) * | 2008-12-19 | 2012-03-28 | 阿斯利康(瑞典)有限公司 | 1,3,4-噁二唑衍生物及其治疗糖尿病的用途 |
EP3366686B9 (de) | 2009-03-20 | 2021-08-04 | Metabasis Therapeutics, Inc. | Inhibitoren von diacylglycerin-o-acyltransferase 1 (dgat-1) und verwendungen davon |
MX2011011178A (es) | 2009-04-21 | 2011-12-06 | Astellas Pharma Inc | Compuesto de diaciletilendiamina. |
EP2443096A1 (de) | 2009-06-19 | 2012-04-25 | AstraZeneca AB | Pyrazincarboxamide als dgat1-hemmer |
FR2963005B1 (fr) * | 2010-07-23 | 2012-08-17 | Sanofi Aventis | Derives d'oxadiazoles et de pyridazines, leur preparation et leur application en therapeutique |
EP2683704B1 (de) | 2011-03-08 | 2014-12-17 | Sanofi | Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
EP2766349B1 (de) | 2011-03-08 | 2016-06-01 | Sanofi | Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
US8710050B2 (en) | 2011-03-08 | 2014-04-29 | Sanofi | Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
EP2683705B1 (de) | 2011-03-08 | 2015-04-22 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
EP2683700B1 (de) | 2011-03-08 | 2015-02-18 | Sanofi | Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
WO2014054053A1 (en) * | 2012-10-03 | 2014-04-10 | Advinus Therapeutics Limited | Spirocyclic compounds, compositions and medicinal applications thereof |
Family Cites Families (73)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4983731A (en) * | 1989-03-17 | 1991-01-08 | Nebraska Department Of Economic Development | Separation and purification of sugar esters |
US5491172A (en) * | 1993-05-14 | 1996-02-13 | Warner-Lambert Company | N-acyl sulfamic acid esters (or thioesters), N-acyl sulfonamides, and N-sulfonyl carbamic acid esters (or thioesters) as hypercholesterolemic agents |
IL109431A (en) | 1993-05-14 | 2001-01-11 | Warner Lambert Co | Pharmaceutical compositions containing n-acyl sulfamic acid esters (or thioesters), n-acyl sulfonamides, and n-sulfonyl carbamic acid esters (or thioesters), for regulating plasma cholesterol concentration, and certain such novel compounds |
US20030167483A1 (en) * | 1998-06-24 | 2003-09-04 | Farese Robert V. | Diacylglycerol O-acyltransferase |
WO2000058491A1 (fr) | 1999-03-25 | 2000-10-05 | The Kitasato Institute | Nouvelles substances kf-1040t4a, kf-1040t4b, kf-1040t5a et kf-1040t5b et leur procede de production |
GB0021670D0 (en) * | 2000-09-04 | 2000-10-18 | Astrazeneca Ab | Chemical compounds |
CA2369967A1 (en) | 2001-02-12 | 2002-08-12 | Joseph Anthony Cornicelli | Methods of treating nuclear factor-kappa b mediated diseases and disorders |
JP4436129B2 (ja) * | 2001-08-31 | 2010-03-24 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | ジアリールシクロアルキル誘導体、その製造法及びppar−活性剤としてのその使用 |
DE10223273A1 (de) | 2002-05-24 | 2003-12-04 | Aventis Pharma Gmbh | Diarylcycloalkylderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
WO2008011131A2 (en) | 2006-07-21 | 2008-01-24 | Takeda Pharmaceutical Company Limited | Amide compounds |
FR2840301B1 (fr) * | 2002-05-29 | 2007-03-23 | Sanofi Synthelabo | Derives de phenyl-cyclohexyl-propanolamine, leur preparation et leur applicaton en therapeutique |
CA2490972C (en) * | 2002-07-09 | 2012-05-29 | Bristol-Myers Squibb Company | Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method |
NZ537603A (en) * | 2002-07-12 | 2006-09-29 | Sanofi Aventis Deutschland | Heterocyclically substituted benzoylureas, method for their production and their use as medicaments |
JP4164645B2 (ja) | 2002-08-09 | 2008-10-15 | 株式会社大塚製薬工場 | Dgat阻害剤 |
KR100772297B1 (ko) | 2002-11-22 | 2007-11-02 | 니뽄 다바코 산교 가부시키가이샤 | 융합 비시클릭 질소-함유 헤테로사이클 |
AR044152A1 (es) * | 2003-05-09 | 2005-08-24 | Bayer Corp | Derivados de alquilarilo, metodo de preparacion y uso para el tratamiento de la obesidad |
JP2007501801A (ja) | 2003-08-07 | 2007-02-01 | 日本たばこ産業株式会社 | ピロロ[1,2−b]ピリダジン誘導体 |
GB0325192D0 (en) * | 2003-10-29 | 2003-12-03 | Astrazeneca Ab | Method of use |
WO2005046670A1 (en) | 2003-11-11 | 2005-05-26 | The Skinny Drink Company | Composition for prevention and treatment of obesity, cardiovascular and coronary artery disease |
AU2004311909A1 (en) * | 2003-12-22 | 2005-07-21 | Eli Lilly And Company | Triazole, oxadiazole and thiadiazole derivative as PPAR modulators for the treatment of diabetes |
JP2005206492A (ja) | 2004-01-21 | 2005-08-04 | Sankyo Co Ltd | スルホンアミド化合物 |
WO2005072740A2 (en) | 2004-01-30 | 2005-08-11 | Japan Tobacco Inc. | Anorectic compounds |
US20070249620A1 (en) * | 2004-07-02 | 2007-10-25 | Hitoshi Kurata | Urea Derivative |
WO2006019020A1 (ja) | 2004-08-16 | 2006-02-23 | Sankyo Company, Limited | 置換されたウレア化合物 |
EP1805156B1 (de) | 2004-10-15 | 2010-12-22 | Bayer HealthCare LLC | Herstellung und anwendung von biphenyl-4-yl-carbonylaminosäurederivaten zur behandlung von obesitas |
GB0427328D0 (en) * | 2004-12-14 | 2005-01-19 | Astrazeneca Ab | Chemical compounds |
AU2005315430B2 (en) * | 2004-12-14 | 2010-05-27 | Astrazeneca Ab | Oxadiazole derivatives as DGAT inhibitors |
WO2006082952A1 (ja) | 2005-02-01 | 2006-08-10 | Takeda Pharmaceutical Company Limited | アミド化合物 |
KR100883694B1 (ko) | 2005-02-07 | 2009-02-12 | 에프. 호프만-라 로슈 아게 | 디아실글리세롤 아실트랜스퍼라제 억제제 |
US20090215780A1 (en) | 2005-04-19 | 2009-08-27 | Bayer Pharmaceuticals Corporation | Preparation and Use of Aryl Alkyl Acid Derivatives for the Treatment of Obesity |
BRPI0608906A2 (pt) | 2005-05-10 | 2010-02-17 | Hoffmann La Roche | composto, processo para a sua manufatura, utilização do mesmo, método para o tratamento de obesidade, diabetes do tipo ii ou sìndrome metabólica e composição farmacêutica que compreende o composto |
US20090215779A1 (en) * | 2005-06-11 | 2009-08-27 | Roger John Butlin | Oxadiazole derivatives as dgat inhibitors |
EP1912634A4 (de) | 2005-07-29 | 2010-06-09 | Bayer Healthcare Llc | Zubereitung und verwendung von biphenyl-aminosäurederivaten zur behandlung von fettleibigkeit |
JP2007131584A (ja) | 2005-11-11 | 2007-05-31 | Sankyo Co Ltd | 新規ベンゾオキサゾール誘導体 |
US7714126B2 (en) * | 2005-11-28 | 2010-05-11 | Via Pharmaceuticals, Inc. | Diacylglycerol acyltransferase inhibitors |
JP2007191471A (ja) | 2005-12-21 | 2007-08-02 | Sankyo Co Ltd | ウレア誘導体を含有する医薬 |
AR058562A1 (es) | 2005-12-22 | 2008-02-13 | Astrazeneca Ab | Derivados de pirimido [4,5 b] (1,4) oxazinas , procedimientos de obtencion y su uso como inhibidores de acetil coa y dgat 1 |
ES2375576T3 (es) | 2006-03-31 | 2012-03-02 | Novartis Ag | Derivados del �?cido (4-(4-[6-(trifluorometil-piridin-3-ilamino)-heteroarilo con contenido de n]-fenil)-ciclohexil)-acético y sus usos farmacéuticos. |
WO2007137103A2 (en) | 2006-05-19 | 2007-11-29 | Abbott Laboratories | Inhibitors of diacylglycerol o-acyltransferase type 1 enzyme |
WO2007137107A2 (en) | 2006-05-19 | 2007-11-29 | Abbott Laboratories | Inhibitors of diacylglycerol o-acyltransferase type 1 enzyme |
EP2041099A1 (de) | 2006-05-30 | 2009-04-01 | AstraZeneca AB | 1,3,4-oxadiazolderivate als dgat1-inhibitoren |
US20090209602A1 (en) * | 2006-06-06 | 2009-08-20 | Roger John Butlin | Chemical compounds |
ATE500251T1 (de) | 2006-06-08 | 2011-03-15 | Astrazeneca Ab | Benzimidazole und ihre verwendung zur behandlung von diabetes |
GB0611506D0 (en) * | 2006-06-10 | 2006-07-19 | Astrazeneca Ab | Chemical compounds |
GB0611507D0 (en) * | 2006-06-10 | 2006-07-19 | Astrazeneca Ab | Chemical compounds |
GB0611552D0 (en) | 2006-06-12 | 2006-07-19 | Astrazeneca Ab | Chemical compounds |
WO2008011130A2 (en) | 2006-07-21 | 2008-01-24 | Takeda Pharmaceutical Company Limited | Amide compounds |
US7569590B2 (en) * | 2006-09-19 | 2009-08-04 | Bristol-Myers Squibb Company | Use of thianecarboxamides as dgat inhibitors |
KR100811100B1 (ko) | 2006-09-27 | 2008-03-06 | 한국생명공학연구원 | 벤즈아졸 유도체를 유효성분으로 함유하는 대사성 질환예방 및 치료용 약학적 조성물 |
KR100795462B1 (ko) | 2006-09-27 | 2008-01-16 | 한국생명공학연구원 | 인돌 유도체, 이의 제조방법 및 이를 유효성분으로함유하는 대사성 질환 예방 및 치료용 약학적 조성물 |
BRPI0717845A2 (pt) | 2006-10-04 | 2015-06-16 | Hoffmann La Roche | Uso de compostos, composições farmacêuticas e métodos para o tratamento e/ou profilaxia de enfermidades que podem ser tratadas com agentes de elevação de colesterol-hdl e compostos |
AR063311A1 (es) | 2006-10-18 | 2009-01-21 | Novartis Ag | Compuestos organicos |
EP2117526B1 (de) | 2006-11-29 | 2013-04-03 | Abbott Laboratories | Hemmer von diacylglycerol-o-acyltransferase typ 1 enzym |
EP2120911A1 (de) | 2007-02-15 | 2009-11-25 | Prosidion Limited | Amid- und harnstoffderivate zur behandlung von stoffwechselerkrankungen |
GB0707662D0 (en) | 2007-04-20 | 2007-05-30 | Astrazeneca Ab | Chemical compounds |
CN101720327A (zh) | 2007-04-30 | 2010-06-02 | 雅培制药有限公司 | 二酰甘油o-酰基转移酶1型酶的抑制剂 |
EP2452937A1 (de) | 2007-04-30 | 2012-05-16 | Abbott Laboratories | Inhibitoren des Diacylglycerol-O-acyltransferase-Enzyms vom Typ 1 |
AU2008253118B2 (en) | 2007-05-22 | 2013-11-21 | Madrigal Pharmaceuticals, Inc. | Diacylglycerol acyltransferase inhibitors |
US8058299B2 (en) * | 2007-05-22 | 2011-11-15 | Via Pharmaceuticals, Inc. | Diacylglycerol acyltransferase inhibitors |
EP2152269B1 (de) | 2007-06-08 | 2014-04-23 | Janssen Pharmaceutica, N.V. | Piperidin-/piperazinderivate |
CA2687912C (en) | 2007-06-08 | 2015-11-03 | Janssen Pharmaceutica N.V. | Piperidine/piperazine derivatives |
WO2008148868A1 (en) | 2007-06-08 | 2008-12-11 | Janssen Pharmaceutica N.V. | Piperidine/piperazine derivatives |
JO2972B1 (en) | 2007-06-08 | 2016-03-15 | جانسين فارماسوتيكا ان. في | Piperidine / piperazine derivatives |
WO2009011285A1 (ja) | 2007-07-13 | 2009-01-22 | Taisho Pharmaceutical Co., Ltd. | ヘテロアリールベンゼン化合物 |
US20090036425A1 (en) | 2007-08-02 | 2009-02-05 | Pfizer Inc | Substituted bicyclolactam compounds |
CA2695434A1 (en) | 2007-08-17 | 2009-02-26 | Astrazeneca Ab | Chemical compounds 979 |
US20090076275A1 (en) | 2007-09-19 | 2009-03-19 | David Robert Bolin | Diacylglycerol acyltransferase inhibitors |
AR066169A1 (es) | 2007-09-28 | 2009-07-29 | Novartis Ag | Derivados de benzo-imidazoles, utiles para trastornos asociados con la actividad de dgat |
WO2009071483A1 (en) | 2007-12-07 | 2009-06-11 | Via Pharmaceuticals, Inc. | 1- (indaz0l-5-yl) -ureas as diacylglycerol acyltransferase inhibitors |
WO2009081195A1 (en) | 2007-12-20 | 2009-07-02 | Astrazeneca Ab | Carbamoyl compounds as dgat1 inhibitors 190 |
US8247220B2 (en) * | 2008-02-01 | 2012-08-21 | Kimberly-Clark Worldwide, Inc. | Optical indicator for detecting bacterial pathogens |
WO2009112445A1 (en) | 2008-03-10 | 2009-09-17 | Novartis Ag | Method of increasing cellular phosphatidyl choline by dgat1 inhibition |
CN102395572A (zh) * | 2008-12-19 | 2012-03-28 | 阿斯利康(瑞典)有限公司 | 1,3,4-噁二唑衍生物及其治疗糖尿病的用途 |
-
2007
- 2007-05-29 CN CN2007800203199A patent/CN101472905B/zh not_active Expired - Fee Related
- 2007-05-29 DE DE602007011446T patent/DE602007011446D1/de active Active
- 2007-05-29 MX MX2008015228A patent/MX2008015228A/es active IP Right Grant
- 2007-05-29 CA CA002651710A patent/CA2651710A1/en not_active Abandoned
- 2007-05-29 EP EP07733006A patent/EP2041100B1/de active Active
- 2007-05-29 KR KR1020087029467A patent/KR20090012349A/ko not_active Application Discontinuation
- 2007-05-29 NZ NZ572586A patent/NZ572586A/en not_active IP Right Cessation
- 2007-05-29 JP JP2009512664A patent/JP2009538892A/ja active Pending
- 2007-05-29 US US12/302,185 patent/US8084478B2/en not_active Expired - Fee Related
- 2007-05-29 AU AU2007266796A patent/AU2007266796B2/en not_active Ceased
- 2007-05-29 AT AT07733006T patent/ATE492541T1/de not_active IP Right Cessation
- 2007-05-29 WO PCT/GB2007/001990 patent/WO2007138311A1/en active Application Filing
- 2007-05-29 BR BRPI0712802-9A patent/BRPI0712802A2/pt not_active IP Right Cessation
- 2007-05-29 ES ES07733006T patent/ES2356097T3/es active Active
-
2008
- 2008-11-05 IL IL195126A patent/IL195126A0/en unknown
- 2008-11-10 NO NO20084732A patent/NO20084732L/no not_active Application Discontinuation
- 2008-11-13 ZA ZA200809690A patent/ZA200809690B/xx unknown
-
2009
- 2009-07-22 HK HK09106693.8A patent/HK1128687A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
EP2041100A1 (de) | 2009-04-01 |
IL195126A0 (en) | 2011-08-01 |
BRPI0712802A2 (pt) | 2012-10-23 |
ZA200809690B (en) | 2010-04-28 |
US20090275620A1 (en) | 2009-11-05 |
MX2008015228A (es) | 2008-12-12 |
AU2007266796A1 (en) | 2007-12-06 |
AU2007266796B2 (en) | 2011-02-10 |
DE602007011446D1 (en) | 2011-02-03 |
HK1128687A1 (en) | 2009-11-06 |
EP2041100B1 (de) | 2010-12-22 |
CA2651710A1 (en) | 2007-12-06 |
KR20090012349A (ko) | 2009-02-03 |
ES2356097T3 (es) | 2011-04-04 |
US8084478B2 (en) | 2011-12-27 |
ATE492541T1 (de) | 2011-01-15 |
WO2007138311A1 (en) | 2007-12-06 |
CN101472905A (zh) | 2009-07-01 |
NZ572586A (en) | 2011-03-31 |
CN101472905B (zh) | 2011-12-14 |
JP2009538892A (ja) | 2009-11-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20084732L (no) | Substituerte 5-fenylamino- 1, 3, 4-oksadiazol-2-ylcarbonylamino-4-fenoksy-cycloheksane karboksylsyre som inhibitorer av acetyl koenzym A diacylglyserol acyltransferase | |
NO20084663L (no) | 1,3,4-oksadiazol-derivater som DGAT1 inhibitorer | |
NO20085216L (no) | Benzimidazoler og deres anvendelse i behandlingen av diabetes | |
DK1899325T3 (da) | Imidazolinon- og hydantoinderivater som hidtil ukendte hæmmere af histondeacetylase | |
DK1981874T3 (da) | Aminophenylderivater som nye inhibitorer af histondeacetylase | |
HK1128286A1 (en) | Heterocyclylalkyl derivatives as inhibitors of histone deacetylase | |
RS53080B (en) | AMINOPHOSPHORIC ACID ETHAR DERIVATIVE AND S1P RECEPTOR MODULATOR CONTAINING THE SAME AS THE ACTIVE INGREDIENT | |
WO2009024821A3 (en) | Oxadiazole derivatives as dgat inhibitors | |
DK1943232T3 (da) | Kvadratsyrederivater som inhibitorer af histondeacetylase | |
EA200900631A1 (ru) | Замещённые пиразолы и триазолы, как ингибиторы кбв (кинезин-белок веретена) | |
EA200901325A1 (ru) | [2,6] нафтиридины, применимые в качестве ингибиторов протеинкиназы | |
BR112012027387A2 (pt) | composição para controle de doenças de plantas e uso da mesma | |
ATE519818T1 (de) | Reversibel thermochrome zusammensetzung | |
MY161036A (en) | Diphenyl sulfide derivative and pharmaceutical product which contains same as active ingredient | |
MY150546A (en) | New piperidine compounds, a process for their preparation and pharmaceutical compositions containing them | |
TH88501A (th) | สารยับยั้งคิเนส | |
TH88501B (th) | สารยับยั้งคิเนส | |
TW200700385A (en) | Racemic and optically active 4-chloro-3-(5-chloro-3-alkyl-2-oxo-2,3-dihydro-1h-indol-3-yl)benzoic acid derivatives and the preparation thereof | |
TH89781B (th) | 3-อะมิโน-2-อัลริลโพรพิล อะซาอินโดลและการใช้ของสิ่งเหล่านี้ | |
TN2010000324A1 (en) | New piperidine compounds a process for their preparation and pharmaceutical compositions containing them | |
TH86644A (th) | อนุพันธ์ของ 5-พิริดาไซนิล-1-อะซาไบไซโคล[3.2.1]ออกเทน, การเตรียมสารนั้นและการใช้สารนั้นรักษาโรค | |
TH90405A (de) | ||
TH87625B (th) | (6-ฟลูออโร-เบนโซ[1,3]ไดออกโซอิล)-มอร์ฟอลิน-4-อิล-เมธาโนน | |
TH88614A (th) | สารประกอบใหม่ | |
TH89781A (th) | 3-อะมิโน-2-อัลริลโพรพิล อะซาอินโดลและการใช้ของสิ่งเหล่านี้ |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |